Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00286988
Other study ID # TOPMAT-EME-4001
Secondary ID
Status Terminated
Phase Phase 4
First received February 1, 2006
Last updated January 5, 2011
Start date March 2006
Est. completion date June 2007

Study information

Verified date April 2007
Source Monarch Medical Research
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the effectiveness, tolerability and safety of oral topiramate for the preventative management of Cyclic Vomiting Syndrome. It is believed that topiramate will decrease the frequency, duration and severity of attacks experienced by children and adolescents with Cyclic Vomiting Syndrome.


Description:

There is very little controlled data on the preventative treatment for Cyclic Vomiting Syndrome. The existing evidence consists of small, retrospective clinical series that evaluate symptomatic responses to five medications including cyproheptadine, propranolol, amitriptyline, phenobarbital and pizotifen (n >10). These published data consist of uncontrolled or retrospective reports. In addition, varying inclusion criteria and outcomes (i.e. obtained by family recall) were used in these studies limiting the basis upon which to compare relative effectiveness.

During the prospective baseline period, the subject will maintain cyclical vomiting records in which all headache occurrences will be recorded and characterized. (Cyclical vomiting records will be maintained throughout the study). The purpose of this study is to assess the effectiveness, tolerability and safety of oral topiramate for the preventative management of Cyclic Vomiting Syndrome using a prospective design, established diagnostic criteria (ICHD 2004), and defined, objective primary and secondary endpoints.


Recruitment information / eligibility

Status Terminated
Enrollment 12
Est. completion date June 2007
Est. primary completion date May 2007
Accepts healthy volunteers No
Gender Both
Age group 4 Years to 12 Years
Eligibility Inclusion Criteria:

- Meet the2004 ICHD Criteria for Cyclical Vomiting.

- 1 vomiting attack lasting > 24 hours duration for 3 consecutive months

- 4-12 years of age.

- If female, subjects must:

1. be premenarchal or otherwise incapable of pregnancy, or

2. have practiced one of the following methods of contraception for at least one month prior to study entry: hormonal contraceptives, spermicide and barrier, intrauterine device, partner sterility, or

3. be practicing abstinence and agree to continue abstinence or to use an acceptable method of contraception (as listed above) should sexual activity commence.

- Able to take oral medication in tablet form or sprinkle form

- Subjects or their guardians must be willing and able to: a) read and comprehend written instructions, b) complete the assessment forms, c) return for regular visits, and d) adhere to medication regimens.

- Subjects (or their legally acceptable representative) must have signed an informed consent document

Exclusion Criteria

- Have taken topiramate within 14 days prior to the start of the prospective baseline period.

- Have taken certain medications for cyclical vomiting prophylaxis

- Have progressive neurological disorder or a structural disorder of the brain from birth, trauma or past infection.

- Subjects who have taken any medications for migraine prophylaxis, within 2 weeks of the start of the prospective baseline period.

- Subjects starting non-pharmacologic prophylactic approaches (e.g., acupuncture, biofeedback, chiropractic methods) within 1 month prior to Visit 1.

- Require continuing treatment with anticonvulsant therapy for a non-migraine condition.

- Significant major psychiatric disorder (e.g., major depression) or subjects receiving anti-psychotic medication.

- History of attempted suicide or suicidal tendencies.

- History of substance abuse.

- Pregnant or lactating females.

- Have clinically unstable neurological, cardiovascular, gastrointestinal, musculoskeletal, pulmonary or other disease.

- Have any disease or condition that could compromise the function of those body systems that could result in altered absorption, excess accumulation, or impaired metabolism or excretion of the test medications (e.g., abnormal renal and/or hepatic function).

- Have active liver disease.

- Have received an investigational drug or used an investigational device within 30 days of study entry.

- Employees of the investigator, study center, or sponsor (i.e., principal investigator, sub-investigator(s), study coordinators, other study staff, employees, or contractors of each), with direct involvement in the proposed study or other studies under the direction of that investigator, study center or sponsor, as well as family members of the employees or the investigator.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Drug:
Topiramate


Locations

Country Name City State
United States Monarch Medical Research - Child and Adolescent Neurology Norfolk Virginia

Sponsors (2)

Lead Sponsor Collaborator
Monarch Medical Research Ortho-McNeil Neurologics, Inc.

Country where clinical trial is conducted

United States, 

References & Publications (2)

Abu-Arafeh I, Russell G. Prevalence and clinical features of abdominal migraine compared with those of migraine headache. Arch Dis Child. 1995 May;72(5):413-7. — View Citation

CULLEN KJ, MA CDONALD WB. The periodic syndrome: its nature and prevalence. Med J Aust. 1963 Aug 3;50(2):167-73. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Reduction of cycle frequency as measured by number of days between cycles.
Secondary Decreased duration of attacks (measured in hours)
Secondary Decreased intensity of attacks (0-4 point scale; none, mild, moderate, severe, excruciating)
Secondary Decreased associated symptoms (0-4 point scales; none, mild, moderate, severe, excruciating)
Secondary Nausea
Secondary Vomiting
Secondary Headache
Secondary Abdominal pain
Secondary Decreased disability
Secondary PedMidas
Secondary Missed school (days per attack)
Secondary Missed work (parent(s)) (days per attack)
Secondary Decreased use of acute therapies (e.g. anti-emetics)
Secondary Decreased emergency department visits.
See also
  Status Clinical Trial Phase
Completed NCT00358813 - Observational Pharmacokinetic Study Of GW679769 In Subjects With Renal Impairment Phase 1
Recruiting NCT03851835 - Multi-DOSE Oral Ondansetron for Pediatric Acute GastroEnteritis Phase 3
Terminated NCT01649258 - Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy Phase 1
Terminated NCT01975727 - Dexamethasone for the Treatment of Established Postoperative Nausea and Vomiting Phase 2
Completed NCT02939287 - Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan Phase 3
Not yet recruiting NCT06464926 - Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System (NAVIGATE) N/A
Completed NCT02462811 - A Double-Blind, Randomized, Active- and Placebo-Controlled, Multiple-Dose Multi-Center Phase 3 Study of the Safety and Efficacy of CL-108 in the Treatment of Moderate to Severe Acute Pain and Opioid-Induced Nausea and Vomiting (OINV) Phase 3
Recruiting NCT01966406 - Is Nasogastric Tube Necessary After Pancreaticoduodenectomy? N/A
Completed NCT01007500 - Effect of Dexamethasone Combined With Ondansetron on Postoperative Nausea and Vomiting in Patients With Patient-controlled Analgesia After Video-assisted Thoracoscopic Surgery Phase 4
Recruiting NCT00528554 - Laser Acupuncture Against Nausea in Children N/A
Completed NCT00537875 - Evaluation of the Effect of Zingiber Officinalis on Nausea and Vomiting in Patients Receiving Cisplatin Based Regimens N/A
Completed NCT00394966 - A Multicenter, Randomized, Controlled Trial of SCH 619734 for the Treatment of Chemotherapy-Induced Nausea and Vomiting (Study P04351AM2)(COMPLETED) Phase 2
Completed NCT00177333 - Serum Levels of Doxycycline at the Time of Abortion With Two Dosing Regimens Phase 4
Completed NCT00946387 - To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Fasting Conditions Phase 1
Completed NCT00947128 - To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Non-Fasting Conditions Phase 1
Not yet recruiting NCT04827108 - Psychometric Properties of the Chinese Version of PeNAT
Not yet recruiting NCT04853303 - VR to Improve CINV, Sleep and Pain Among Children With Cancer in HK N/A
Recruiting NCT03679182 - Efficacy and Safety of Olanzapine for the Treatment of Nausea and Vomiting in Palliative Cancer Care Phase 2
Terminated NCT01405924 - Fosaprepitant (MK-0517, EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030) Phase 2
Recruiting NCT04116697 - A Randomized Controlled Trial to Evaluate the Efficacy of Acupuncture Versus Aromatherapy as Treatments to Lessen Nausea, Vomiting and Anxiety Associated With Adriamycin and Cytoxan N/A